New Treatment Shows Promise for Pancreatic Cancer
胰臟癌新療法展現潛力
For decades, pancreatic cancer has been viewed with a sense of helplessness, often termed an almost automatic terminal diagnosis.
數十年來，胰臟癌常被視為令人束手無策的疾病，通常被認為是一種幾乎等同於絕症的診斷。
Recent breakthroughs are challenging the status quo, with two new drugs leading the way.
近期的重大突破正在挑戰現狀，其中兩款新藥引領風騷。
Daraxonrasib has shown a remarkable ability to nearly double median survival rates by targeting the elusive KRAS mutation, long considered 'undruggable.'
Daraxonrasib透過標靶長期被認為「無法藥物治療」的頑固KRAS突變，顯示出能將中位存活率提升近一倍的驚人功效。
Meanwhile, Elraglusib is changing the game by breaking down the dense, protective web surrounding tumors, allowing chemotherapy to reach cancer cells more effectively.
與此同時，Elraglusib則透過分解圍繞在腫瘤周圍那層緻密的保護網，使化療能更有效地觸及癌細胞，從而改變了治療格局。
Beyond these treatments, researchers are exploring 'cancer interception,' which aims to eliminate precancerous lesions before they ever become full-blown tumors.
除此等治療外，研究人員正探索「癌症攔截」，目標是在癌前病變演變成完全的腫瘤之前將其消除。
By moving away from a one-size-fits-all approach toward personalized medicine—focusing on the unique genetic profile of each tumor—scientists are beginning to view pancreatic cancer as a manageable condition.
透過拋棄「一體適用」的方法，轉而採取針對每個腫瘤獨特基因組成的個人化醫療，科學家們正開始將胰臟癌視為一種可控的狀況。
